アバスチン（ベバシズマブ）の世界市場レポート2025年：疫学、パイプライン分析、市場インサイトと予測

アバスチン（ベバシズマブ）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9%で104億8,900万米ドルに成長します。予測期間の成長は、認知度の向上と早期診断、バイオシミラー競合、個別化医療の成長、ヘルスケアへのアクセス性、精密医療の重視の高まりに起因すると考えられます。予測期間における主要動向としては、併用療法の増加、外来治療へのシフト、患者中心の治療モデル、標的療法の採用、製品の革新などが挙げられます。

がんの有病率の増加は、今後数年間のアバスチン（ベバシズマブ）市場の成長を牽引すると予想されます。がんは、異常細胞の制御不能な増殖と拡散を特徴とする疾患群を包含します。がん罹患率の上昇は、人口の高齢化、ライフスタイルの変化、検出方法の進歩などの要因に起因しています。モノクローナル抗体であるアバスチンは、VEGFを阻害することでがんを治療し、腫瘍に酸素や栄養を供給する血管の形成を妨げ、腫瘍の成長を阻害します。例えば、米国がん協会によると、2022年には米国で新たに約190万人のがん患者と60万9,360人のがん関連死が予測され、これは1日あたり約1,670人の死亡に相当します。このがん負担の増加が、アバスチン市場拡大の大きな要因となっています。

アバスチン（ベバシズマブ）市場の成長は、ヘルスケア支出の増加によって促進されると予想されます。ヘルスケア支出には、健康成果の向上を目的としたパーソナルケア、予防対策、公衆衛生活動など、健康関連の商品やサービスへの支出総額が含まれます。この増加の背景には、高齢化、慢性疾患の蔓延、医療技術の進歩、薬価の高騰、非効率な決済システム、医療サービスに対する需要の高まりといった要因があります。ヘルスケア支出の増加は、保険適用範囲の拡大を通じてアバスチンへのアクセスを容易にし、それによって市場範囲と患者の利用を拡大します。例えば、英国の国家統計局が2024年5月に発表した報告書によると、2022～2023年にかけての総ヘルスケア支出の名目増加率は5.6%であったのに対し、2022年の増加率は0.9%でした。さらに、長期的な医療社会保障支出は2022年に実質ベースで2.8％増加しました。この動向は、ヘルスケアシステムへの投資の増加が、アバスチンのような革新的治療へのアクセスや成長を支え、市場をさらに前進させることを反映しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場：金利、インフレ、地政学、貿易摩擦、コロナ禍と回復を含むマクロ経済の影響

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のアバスチン（ベバシズマブ）：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のアバスチン（ベバシズマブ）市場：成長率分析
• 世界のアバスチン（ベバシズマブ）市場の実績：規模と成長、2019～2024年
• 世界のアバスチン（ベバシズマブ）市場の予測：規模と成長、2024～2029年、2034年
• 世界のアバスチン（ベバシズマブ）：総潜在市場規模（TAM）

第7章 世界市場の価格分析と予測

第8章 市場セグメンテーション

• 世界のアバスチン（ベバシズマブ）市場：投与量別、実績と予測、2019～2024年、2024～2029年、2034年
• 100mg
• 400mg
• 世界のアバスチン（ベバシズマブ）市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 非扁平上皮非小細胞肺がん
• 再発性神経膠芽腫
• 子宮頸がん
• 大腸がん
• 卵巣がん
• 増殖性糖尿病網膜症
• 悪性神経膠腫
• 神経線維腫症
• 膵臓がん
• その他
• 世界のアバスチン（ベバシズマブ）市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 直接入札
• 病院薬局
• 小売薬局
• オンライン薬局
• その他
• 世界のアバスチン（ベバシズマブ）市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• がん支援センター
• 在宅ヘルスケア
• 学術研究機関
• その他

第9章 臨床適応症の世界市場疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のアバスチン（ベバシズマブ）市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のアバスチン（ベバシズマブ）市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• アバスチン（ベバシズマブ）市場：競合情勢
• アバスチン（ベバシズマブ）市場：企業プロファイル
  • Roche Holding AG

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• アバスチン（ベバシズマブ）市場、2029年：新たな機会を提供する国
• アバスチン（ベバシズマブ）市場、2029年：新たな機会を提供するセグメント
• アバスチン（ベバシズマブ）市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

Avastin (bevacizumab) is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), effectively inhibiting angiogenesis-the process by which new blood vessels are formed to supply tumors with oxygen and nutrients. It is commonly used in conjunction with chemotherapy to treat various cancers, including colorectal, lung, kidney, and glioblastoma.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary dosages of avastin (bevacizumab) are 100 mg and 400 mg. The 100 mg dosage form is used to treat a range of cancers by preventing the growth of blood vessels that nourish tumors. Its applications include non-squamous non-small cell lung cancer, recurrent glioblastoma, cervical cancer, colorectal cancer, ovarian cancer, proliferative diabetic retinopathy, malignant glioma, neurofibromatosis, pancreatic cancer, among others. These products are distributed through various channels such as direct tender, hospital pharmacies, retail pharmacies, and online pharmacies. End users include hospitals, cancer care centers, home healthcare providers, academic and research institutes, and others.

The avastin (bevacizumab) market research report is one of a series of new reports from The Business Research Company that provides Avastin (bevacizumab) market statistics, including the Avastin (bevacizumab) industry's global market size, regional shares, competitors with an Avastin (bevacizumab) market share, detailed Avastin (bevacizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the Avastin (bevacizumab) industry. This Avastin (bevacizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The avastin (bevacizumab) market size is expected to see strong growth in the next few years. It will grow to $10,489.0 million in 2029 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to increased awareness and early diagnosis, biosimilar competition, personalized medicine growth, healthcare accessibility, and growing emphasis on precision medicine. Major trends in the forecast period include increasing combination therapies, shift towards outpatient care, patient-centric treatment models, adoption of targeted therapies, and product innovation.

The increasing prevalence of cancer is expected to drive the growth of the avastin (bevacizumab) market in the coming years. Cancer encompasses a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. The rising incidence of cancer can be attributed to factors such as aging populations, lifestyle changes, and advancements in detection methods. Avastin, a monoclonal antibody, treats cancer by inhibiting VEGF, preventing the formation of blood vessels that supply oxygen and nutrients to tumors, thereby impeding tumor growth. For instance, the American Cancer Society reported that in 2022, approximately 1.9 million new cancer cases and 609,360 cancer-related deaths were anticipated in the United States, equivalent to about 1,670 deaths daily. This rising cancer burden is a significant driver of the avastin market's expansion.

The growth of the Avastin (bevacizumab) market is expected to be propelled by rising healthcare expenditure. Healthcare expenditure encompasses the total spending on health-related goods and services, including personal care, preventive measures, and public health activities, aimed at enhancing health outcomes. This increase is driven by factors such as an aging population, the prevalence of chronic diseases, advancements in medical technology, high drug prices, inefficient payment systems, and a growing demand for healthcare services. Elevated healthcare expenditure facilitates greater access to Avastin through improved insurance coverage, thereby broadening its market reach and patient utilization. For example, a report by the UK's Office for National Statistics in May 2024 highlighted a 5.6% nominal increase in total healthcare expenditure from 2022 to 2023, compared to a 0.9% growth rate in 2022. Additionally, long-term health and social care spending rose by 2.8% in real terms in 2022. This trend reflects how increasing investment in healthcare systems supports the accessibility and growth of innovative treatments like Avastin, further driving the market forward.

A key trend shaping the avastin (bevacizumab) market is the development of biosimilars to provide cost-effective alternatives and improve access to cancer treatments. Biosimilars, highly similar in structure, function, and efficacy to Avastin, are transforming oncology care by offering affordable options, particularly in resource-constrained settings. For example, in October 2022, Amneal Pharmaceuticals launched ALYMSYS (bevacizumab-maly), a biosimilar referencing Avastin, in the U.S. This VEGF inhibitor is indicated for various cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, renal cell carcinoma, and gynecologic cancers, demonstrating the potential of biosimilars to enhance treatment accessibility.

Key player operating in the avastin (bevacizumab) market is Roche Holding AG

North America was the largest region in the avastin (bevacizumab) market in 2024. The regions covered in avastin (bevacizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the avastin (bevacizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The avastin (bevacizumab) market consists of sales of intravenous (iv) formulations, and bevacizumab injection. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Avastin (Bevacizumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on avastin (bevacizumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for avastin (bevacizumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The avastin (bevacizumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Dosage: 100 Mg; 400 Mg
• 2) By Application: Non Squamous Non-Small Cell Lung Cancer; Recurrent Glioblastoma; Cervical Cancer; Colorectal Cell Cancer; Ovarian Cancer; Proliferative Diabetic Retinopathy; Malignant Glioma; Neurofibromatosis; Pancreatic Cancer; Other Applications
• 3) By Distribution channel: Direct Tender; Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 4) By End User: Hospitals; Cancer Supportive Centers; Home Healthcare; Academic And Research Institutes; Other End Users
• Companies Mentioned: Roche Holding AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Avastin (Bevacizumab) Market Characteristics

3. Avastin (Bevacizumab) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Avastin (Bevacizumab) Market Trends And Strategies

5. Avastin (Bevacizumab) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Avastin (Bevacizumab) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Avastin (Bevacizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Avastin (Bevacizumab) Market Growth Rate Analysis
• 6.4. Global Avastin (Bevacizumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Avastin (Bevacizumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Avastin (Bevacizumab) Total Addressable Market (TAM)

7. Global Avastin (Bevacizumab) Market Pricing Analysis & Forecasts

8. Avastin (Bevacizumab) Market Segmentation

• 8.1. Global Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 100 Mg
• 400 Mg
• 8.2. Global Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non Squamous Non-Small Cell Lung Cancer
• Recurrent Glioblastoma
• Cervical Cancer
• Colorectal Cell Cancer
• Ovarian Cancer
• Proliferative Diabetic Retinopathy
• Malignant Glioma
• Neurofibromatosis
• Pancreatic Cancer
• Other Applications
• 8.3. Global Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 8.4. Global Avastin (Bevacizumab) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Cancer Supportive Centers
• Home Healthcare
• Academic And Research Institutes
• Other End Users

9. Global Avastin (Bevacizumab) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Avastin (Bevacizumab) Market Regional And Country Analysis

• 10.1. Global Avastin (Bevacizumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Avastin (Bevacizumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Avastin (Bevacizumab) Market

• 11.1. Asia-Pacific Avastin (Bevacizumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Avastin (Bevacizumab) Market

• 12.1. China Avastin (Bevacizumab) Market Overview
• 12.2. China Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Avastin (Bevacizumab) Market

• 13.1. India Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Avastin (Bevacizumab) Market

• 14.1. Japan Avastin (Bevacizumab) Market Overview
• 14.2. Japan Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Avastin (Bevacizumab) Market

• 15.1. Australia Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Avastin (Bevacizumab) Market

• 16.1. South Korea Avastin (Bevacizumab) Market Overview
• 16.2. South Korea Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Avastin (Bevacizumab) Market

• 17.1. Western Europe Avastin (Bevacizumab) Market Overview
• 17.2. Western Europe Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Avastin (Bevacizumab) Market

• 18.1. UK Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Avastin (Bevacizumab) Market

• 19.1. Germany Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Avastin (Bevacizumab) Market

• 20.1. France Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Avastin (Bevacizumab) Market

• 21.1. Eastern Europe Avastin (Bevacizumab) Market Overview
• 21.2. Eastern Europe Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Avastin (Bevacizumab) Market

• 22.1. North America Avastin (Bevacizumab) Market Overview
• 22.2. North America Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Avastin (Bevacizumab) Market

• 23.1. USA Avastin (Bevacizumab) Market Overview
• 23.2. USA Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Avastin (Bevacizumab) Market

• 24.1. Canada Avastin (Bevacizumab) Market Overview
• 24.2. Canada Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Avastin (Bevacizumab) Market

• 25.1. South America Avastin (Bevacizumab) Market Overview
• 25.2. South America Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Avastin (Bevacizumab) Market

• 26.1. Middle East Avastin (Bevacizumab) Market Overview
• 26.2. Middle East Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Avastin (Bevacizumab) Market

• 27.1. Africa Avastin (Bevacizumab) Market Overview
• 27.2. Africa Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Avastin (Bevacizumab) Market Competitive Landscape And Company Profiles

• 28.1. Avastin (Bevacizumab) Market Competitive Landscape
• 28.2. Avastin (Bevacizumab) Market Company Profiles
  • 28.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

29. Global Avastin (Bevacizumab) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Avastin (Bevacizumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Avastin (Bevacizumab) Market

32. Recent Developments In The Avastin (Bevacizumab) Market

33. Avastin (Bevacizumab) Market High Potential Countries, Segments and Strategies

• 33.1 Avastin (Bevacizumab) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Avastin (Bevacizumab) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Avastin (Bevacizumab) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer